# Lenor®

Letrozole USP Film Coated Tablet

## DESCRIPTION

**Lenor®** is a preparation Letrozole. Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. The suppression of estrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.

## INDICATIONS AND USAGES

- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
- Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years prior standard adjuvant tamoxifen therapy.
- First-line treatment in postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer
- Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens.

## DOSAGE AND ADMINISTRATION

- **Adult & Elderly patients:** The recommended dose of **Lenor®** is 2.5 mg once daily. In the adjuvant and extended adjuvant setting, treatment with **Lenor®** should continue for 5 years or until tumour relapse occurs, whichever comes first. In patients with metastatic disease, treatment with **Lenor®** should continue until tumour progression is evident. No dose adjustment is required for elderly patients.
- **Children:** Not applicable.
- **Renal Impairment:** No dosage adjustment is required for patients with renal impairment if creatinine clearance is ≥10 ml/ min.
- **Hepatic Impairment:** No dosage adjustment is required for patients with mild to moderate hepatic impairment. The dose of **Lenor®** in patients with cirrhosis and severe hepatic impairment should be reduced by 50%. The recommended dose for such patient is 2.5 mg administered every other day. The effect of hepatic impairment on **Lenor®** exposure in noncirrhotic women patients with elevated bilirubin level has not been determined.

## CONTRAINDICATIONS

- Known hypersensitivity to the active substance.
- In women having a premenopausal endocrine status, during pregnancy & lactation

## SIDE-EFFECTS

Letrozole tablet is generally well tolerated. The observed adverse reactions are mild to moderate in nature including hot ash, night sweats, weight increase, nausea, vaginal bleeding & irritation, endometrial proliferation disorders.

## USE IN PREGNANCY & LACTATION

Contraindicated during pregnancy and lactation.

## PHARMACEUTICAL PRECAUTION

Keep in a dry & cool place (below 30° C temp.), away from light. Keep out of reach of children.

## PACKAGING

**Lenor®** Tablet : Box containing 1 strip of 10 tablets. Each film coated tablet contains Letrozole USP 2.5 mg.

SK+F

Manufactured for
**ESKAYEF BANGLADESH LIMITED**
By POPULAR PHARMACEUTICALS LTD.
GAZIPUR, BANGLADESH
® REGD.TRADEMARK
PM02834 V01